The Hemangioma Market Size was valued at USD 0.95 Billion in 2023. The Global Hemangioma industry is projected to grow from USD 1.00 Billion in 2024 to USD 1.51 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.02% during the forecast period (2024 - 2032).
Hemangioma is the birthmark or benign tumors of infancy that occurs due to an abnormal collection of blood vessels. This occurs in 5-10% of infants worldwide. Increasing cases of hemangioma, increasing use of technology, and different treatment options are key drivers for the Hemangioma market.
Increasing knowledge about the disorder and treatment, introduction of new drugs and therapies, and rapidly changing medical technology are major driving forces of the market. Increasing investment in R&D to develop more advanced product for the market is another major factor for the market.
Study objectives of Hemangioma Market
Hemangioma Market has been segmented on the basis of type which Capillary hemangioma, Cavernous hemangioma (Cerebral cavernous malformations, Liver cavernous hemangioma, Eye cavernous hemangioma), Compound hemangioma, Lobular capillary hemangioma (pyogenic granuloma), and others. Cavernous hemangioma is further sub-segmented into cerebral cavernous malformations, liver cavernous hemangioma, and Eye cavernous hemangioma.
On the basis of diagnosis, it is segmented into Ultrasound, MRI, CT scan, and others.
On the basis of treatment, the market is segmented into medical therapy, laser therapy, surgery, and others. Medical therapy is further sub-segmented into systemic, intralesional and topical. Laser therapy is sub-segmented into Flash lamp pulsed dye laser, intralesional laser, carbon dioxide laser.
Considering the global scenario of the market, due to continuous innovation and rapid adoption of new drugs and therapies, North America is holding largest market for Hemangioma. In North America region, US attributes largest market share. European market is second largest, and especially the growth rate is higher in west European countries.
On the other hand, developing healthcare infrastructure, and increasing healthcare spending, the Asia-Pacific (APAC) is fastest growing market for Hemangioma and expected to grow significantly during the forecast period. Middle East and Africa (ME&A) is likely to have a limited growth in the market due to less awareness of treatment and products.
The report for Global Hemangioma Market of Market Research Future comprises extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance.
The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market’s segments and regions
Intended Audience
| Attribute/Metric | Details |
| Â Â Market Size 2032 | Â Â USD 1.51 Billion |
| Â Â CAGR | Â 6.02% (2024-2032) |
| Â Â Base Year | Â Â 2023 |
| Forecast Period | Â 2024-2032 |
| Historical Data | Â Â 2020 |
| Forecast Units | Â Â Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Â By Type, Diagnosis, Treatment |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Â Â Key Vendors | Akrimax Pharmaceuticals, LLC. (US), AstraZeneca (UK), Cutting Edge Laser Technologies (US), Linline Medical Systems (France), Novartis AG (Switzerland), Pfizer Inc. (US), Pierre Fabre (US) Quanta System S.p.A. (Italy) |
| Key Market Opportunities | Continuous innovation and rapid adoption of new drugs and therapies Developing healthcare infrastructure, and increasing healthcare spending in the Asia-Pacific (APAC) |
| Key Market Drivers | Increasing investment in R&D to develop more advanced product Rapidly changing medical technology |
Hemangioma Market Highlights:
Frequently Asked Questions (FAQ) :
The hemangioma market valuation would be USD 1.51 Billion by 2032.
The hemangioma market CAGR would be 6.02% during the forecast period.
The diagnosis types included in the hemangioma market are MRI, CT scan, Ultrasound, and others.
The Americas would dominate the hemangioma market.
The Asia Pacific region would record high hemangioma market CAGR.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
| FEATURES | LICENCE TYPE | ||
|---|---|---|---|
| Single User | Multiuser Licence | Enterprise User | |
| Price | $ 4,950 | $ 5,950 | $ 7,250 |
| Maximum User Access Limit | 1 User | Upto 10 Users | Unrestricted Access Throughout The Organization. |
| Free Customization |  |
|
|
| Direct access to the Analyst | |
|
|
| Deliverable Format | |
|
|
 |
|
|
|
| Platform Access | |
|
|
| Discount on Your Next Purchase | 10% | 15% | 10% |
| Printable Versions | |
|
|
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
